Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eradication of Helicobacter Pylori by 14-day Dual Therapy of Keverprazan in Combination With Low-dose and High-dose Amoxicillin: a Prospective, Single-center, Developmental-label, Randomized Controlled Study

NCT06412640 is registered in ClinicalTrials.gov with Nanjing First Hospital, Nanjing Medical University as lead sponsor.

NCT NCT06412640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06412640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eradication of Helicobacter Pylori by 14-day Dual Therapy of Keverprazan in Combination With Low-dose and High-dose Amoxicillin: a Prospective, Single-center, Developmental-label, Randomized Controlled Study
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Phase 4
Overall status
Unknown status
Start date
June 1, 2024
Completion date
February 1, 2025
Enrollment
268 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

h. pylori infection